FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Evidence for efficacy is based on the results from the TALAPRO-2 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric or Gastro-Oesophageal Junction Cancer
Findings from the DESTINY-Gastric02 study
Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom with Symptoms to Investigate for Cancer
Findings from the SYMPLIFY study
Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function Alterations in DDR Genes
Findings from the TRESR study
Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC Who Are Progression-Free to Front-Line ICI at 2 Years
Findings from a retrospective cohort study
Neoadjuvant Nivolumab Plus Ipilimumab is Safe and Orchestrates de novo Immune Responses in Patients with Cervical Squamous Cell Carcinoma
Findings from the COLIBRI study
FDA Grants Accelerated Approval to Glofitamab-gxbm for Selected Relapsed or Refractory Large B-Cell Lymphomas
Evidence for efficacy is based on the results from the NP30179 study
Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with Refractory mCRC
Findings from the FRESCO-2 study
An Abnormal Baseline Geriatric 8 Screening Tool Score Strongly Associates with Increased Long-Term Healthcare Utilisation in Older Patients with Cancer
Findings from a retrospective analysis of older patients with newly diagnosed cancer who underwent G8 screening
Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously Untreated, Unresectable Malignant Pleural Mesothelioma
Findings from the IND227 study
The Largest Randomised Study to Date Points to Low Ipsilateral Breast Tumour Relapse Rates Regardless of Delivering the Boost Sequentially or Simultaneously
Findings from the IMPORT HIGH study
Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping NSCLC
Findings from the VISION study